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Mithramycin (MTM) is an aureolic acid-type polyketide antiobiotic 
produced naturally by the soil bacteria from the Streptomyces 
genus. This compound gained popularity in the 1960’s, 
exhibiting anti-cancer activity by cross-linking GC-rich DNA as a 
divalent cation-coordinated MTM dimer complex, shutting down 
proto-oncogenes and up-regulating anti-angiogenic proteins 
such as c-Myc and p53.  
 
MTM has been used clinically in the past to treat testicular 
carcinoma, chronic and acute myeloid leukemias, and 
hypercalcemia, but its use was discontinued due to poor 
selectivity and extreme side effects. However, MTM has recently 
garnered renewed attention as a candidate for Ewing family 
sarcomas and for combinational therapies. Previous research by 
this lab has shown that a combinational approach of 
biosynthetic analogue generation followed by synthetic 
manipulation has the ability to create MTM derivatives with 
further improved anti-cancer activity. By inactivating the mtmW 
gene, the gene encoding the last acting enzyme in the MTM 
biosynthetic pathway, the three analogues MTM SK (SK), MTM 
SDK (SDK), and MTM SA (SA) are produced.  
 
SK and SDK showed improved anti-cancer activity compared to 
native MTM, but SA was largely discarded due to its decreased 
anti-cancer activity. The decreased activity is likely due to a 
negative charge at physiological pH, which inhibits the binding 
of MTM to DNA. Recently, derivatives of SA have shown 
improved anti-cancer activity compared to SK and SDK. To that 
end, our objectives are to design an improved isolation 
procedure for SA, to further derivatize SA, and to evaluate the 
new analogues with regard to their anti-cancer activity.  
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Mithramycin Analogue Biosynthesis 
Bacteria Growth and Drug Production 
Conclusions 
•  SA was successfully isolated using a strong anion exchange 
column with a quaternary amine and specialized wash and 
elution solutions.  
•  SA derivatization is accomplished by the coupling of a 
primary amine of a desired side chain and the carboxylic 
acid of SA. 
•  A methylation procedure was established for side chains 
requiring modification to prevent multiple additions. 
•  SA derivatives were synthesized from tryptophan, 
phenylalanine, and histidine methyl esters, but will require 
further work to confirm and isolate the products. 
•  Anti-cancer activity of the new SA derivatives will be 
evaluated using leukemia and lung cancer cell lines. SK will 
be evaluated with both cell lines as a benchmark.  
The MTM analogues SA, SK, and SDK are produced by the inactivation of the 
mtmW gene responsible for the last enzyme in the biosynthetic pathway of 
MTM.  
Isolation of SA 
HPLC data of relative drug production by S. argillaceus 
over several days. Peaks for SA, SK, and SDK are labeled.  
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MTM Analogues' Production  
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S. Argillaceus is grown on R5A solid media for 5 days. A 
portion is cut out and transferred to liquid TSB media for two 
days of further promoted growth. A sample of this is 
transferred to R5A liquid media for 5 or more days in order to 
promote drug production. 
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R5A Solid Media TSB Liquid Media R5A Liquid Media 
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Jurkat Cell Culturing Derivatization of SA 
Column characteristics for isolation of SA. Column 52667, a 
strong anion exchange column with quaternary amines, 
was able to separate SA from other analogues.   
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Column 52667 Wash vs Elution 
Wash 2 
Elution 1 
SDK 
SK SA 
Column 52667 was the first major isolation of SA. 
Only SK and SDK came off in washes as shown in 
wash 2 above, while mostly SA came off in elution 1. 
A second pass through the column fully isolates SA 
from the analogues..  
A side chain containing a primary amine is coupled to the 
carboxylic acid of SA to create the new derivatives. We 
used tryptophan, histidine, and phenylalanine as side 
chain additions. An example reaction with tryptophan is 
shown below.    
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MTM-SA and MTM-SA Trp 
MTM SA 
MTM SA Trp 
SA 
SK 
SDK 
New Peak! 
(MTM-SA 
Trp?) 
HPLC spectral analysis revealed a new peak in the MTM-
SA Trp compound compared to SA (impure). The  
histidine and phenylalanine reactions yielded several 
new peaks and require additional testing. 
Certain side chain additions require methylation in 
order to prevent peptide chain formation. We developed 
a methylation procedure, the success of which is shown 
above in the IR data of Trp (top), a Trp methylation 
reaction (middle), and stock Trp methyl ester (bottom).  
Jurkat leukemia cells are being culture for cytotoxicity assays 
to evaluate the anticancer activity of the SA derivatives.  
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